Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody
Year: 2013
Type: article
Abstract: A major mechanism by which human regulatory T cells (T(regs)) have been shown to suppress and kill autologous immune cells is through the granzyme-perforin pathway. However, it is unknown whether T(regs) also possess the capacity to kill tumor cells using similar mechanisms. Bispecific antibodies (bscAbs) have emerged as a promising class of therapeutics that activate T cells against tumor antigens without the need for classical MHC-restricted TCR recognition. Here, we show that a bscAb targeting the tumor-specific mutation of the epidermal growth factor receptor, EGFRvIII, redirects human CD4(+)CD25(+)FoxP3(+) T(regs) to kill glioblastoma (GBM) cells. This activity was significantly abrogated by inhibitors of the granzyme-perforin pathway. Notably, analyses of human primary GBM also displayed diffuse infiltration of granzyme-expressing FoxP3(+) T cells. Together, these data suggest that despite their known suppressive functions, tumor-infiltrating T(regs) possess potent cytotoxic mechanisms that can be co-opted for efficient tumor cell lysis.
Source: Cancer Immunology Research
Institution: Duke Medical Center
Language: English
Topic: T-cell and B-cell Immunology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Awards: RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells, SRC on Primary Tumors of the CNS, Medical Scientist Training Program, NINDS Research Education Programs for Residents and Fellows in Neurosurgery, G3199277650, G4050337649, G53543037, G7650321139, Targeting EGFRvIII in Brain Tumors with Bispecific Antibodies, G8185792080, Medical Scientist Training Program Training Grant
OpenAlex ID: W2096822862
